PMID- 36579921
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20240319
IS  - 2378-8763 (Electronic)
IS  - 2578-5125 (Print)
IS  - 2378-8763 (Linking)
VI  - 8
IP  - 6
DP  - 2023 Dec
TI  - The Quebec Cannabis Registry: Investigating the Safety and Effectiveness of 
      Medical Cannabis.
PG  - 1106-1116
LID - 10.1089/can.2022.0041 [doi]
AB  - Objective: To investigate the safety and effectiveness of medical cannabis (MC) 
      in the real-world clinical practice setting. Design: A 4-year prospective 
      noncomparative registry of adult patients who initiated MC for a variety of 
      indications. This paper reports on patients followed for up to 12 months, with 
      interim visits at 3, 6, and 9 months after enrollment. Setting: Public or private 
      outpatient clinics certified to authorize MC in the province of Quebec, Canada. 
      Participants: Overall, 2991 adult (age >/=18 years) patients (mean age 51 years; 
      50.2% women) were enrolled between May 2015 and October 2018, with the last 
      follow-up ending in May 2019. Interventions/Exposures: Cannabis products (dried, 
      oil, or other) purchased from a Canadian licensed cannabis producer as authorized 
      by physicians. Main Outcome Measures: The primary outcomes were self-reported 
      pain severity, interference and relief (Brief Pain Inventory [BPI]), symptoms 
      using the Revised Edmonton Symptom Assessment System (ESAS-r) and health-related 
      quality of life dimensions (EQ-5D-5L) at baseline and each follow-up visit. The 
      secondary outcomes were self-reported adverse events (AEs) and characteristics of 
      cannabis treatment. Results: All patient-reported outcomes (BPI, ESAS-r, and 
      EQ-5D-5L) showed a statistically significant improvement at 3 months (all 
      p<0.01), which was maintained or further improved (for pain interference, 
      tiredness, and well-being) over the remainder of the 12-month follow-up. Results 
      also revealed clinically significant improvements in pain interference and 
      tiredness, anxiety, and well-being from baseline. There were 79 AE reports (77 
      patients), 16 met the regulatory definition of seriousness, in which only 8 AEs 
      were certainly or probably related to MC. Conclusions: MC directed by physicians 
      appears to be safe and effective within 3 months of initiation for a variety of 
      medical indications.
FAU - Vigano, Antonio
AU  - Vigano A
AD  - Medical Cannabis Program in Oncology, Cedars Cancer Center, McGill University 
      Health Centre, Montreal, Canada.
FAU - Moride, Yola
AU  - Moride Y
AD  - Faculty of Pharmacy, University of Montreal, Montreal, Canada.
AD  - Rutgers The State University of New Jersey, Center for Pharmacoepidemiology and 
      Treatment Science, New Brunswick, New Jersey, USA.
FAU - Hachem, Yasmina
AU  - Hachem Y
AUID- ORCID: 0000-0002-3475-8915
AD  - Medical Cannabis Program in Oncology, Cedars Cancer Center, McGill University 
      Health Centre, Montreal, Canada.
FAU - Canac-Marquis, Michelle
AU  - Canac-Marquis M
AD  - Research Institute of the McGill University Health Centre, Montreal, Canada.
FAU - Gamaoun, Rihab
AU  - Gamaoun R
AD  - Medical Cannabis Program in Oncology, Cedars Cancer Center, McGill University 
      Health Centre, Montreal, Canada.
FAU - Kalaba, Maja
AU  - Kalaba M
AUID- ORCID: 0000-0002-3628-5197
AD  - Canopy Growth Corporation, Smiths Falls, Canada.
FAU - Martel, Marc O
AU  - Martel MO
AD  - Faculty of Dentistry & Department of Anesthesia, McGill University, Montreal, 
      Canada.
FAU - Perez, Jordi
AU  - Perez J
AD  - Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, 
      Canada.
FAU - Neron, Andree
AU  - Neron A
AD  - McGill University Health Centre, Montreal, Canada.
FAU - Beaulieu, Pierre
AU  - Beaulieu P
AD  - Department of Anesthesiology & Pain Medicine, Universite de Montreal Faculte de 
      Medecine, Montreal, Canada.
FAU - Desroches, Julie
AU  - Desroches J
AD  - Departement de Pharmacologie, Universite de Montreal, Montreal, Canada.
FAU - Ware, Mark
AU  - Ware M
AD  - Department of Family Medicine, McGil University, Montreal, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221228
PL  - United States
TA  - Cannabis Cannabinoid Res
JT  - Cannabis and cannabinoid research
JID - 101684827
RN  - 0 (Medical Marijuana)
RN  - 0 (Hallucinogens)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Adolescent
MH  - Male
MH  - *Medical Marijuana/adverse effects
MH  - *Cannabis/adverse effects
MH  - Quebec/epidemiology
MH  - Quality of Life
MH  - Prospective Studies
MH  - Canada
MH  - Pain/drug therapy
MH  - *Hallucinogens
MH  - Fatigue/drug therapy
MH  - Registries
PMC - PMC10714117
OTO - NOTNLM
OT  - effectiveness
OT  - medical cannabis
OT  - pain
OT  - quality of life
OT  - registry
OT  - safety
COIS- M.W. initiated the QCR in 2015 and was the Principal Investigator until July 1, 
      2018, when he joined Canopy Growth Corporation, initially as Medical Director and 
      most recently as Consultant. He has since served as a nonvoting Advisory Board 
      member to the QCR. As of July 1, 2018, the QCR was lead by Dr. William Barakett 
      (in memoriam) until March 2019 and is presently lead by A.V. A.V. is currently an 
      advisory board member for EmpowerPharm and has formerly served in this capacity 
      for Spectrum Therapeutics/Canopy Health, Tilray, Tetrabiopharma, Syqe. He was the 
      former Research Director of Sante Cannabis in Montreal, Canada. Y.M. was a 
      consultant for Spectrum Therapeutics/Canopy Health. No other authors have 
      disclosures or conflicts of interest to declare.
EDAT- 2022/12/30 06:00
MHDA- 2023/12/17 09:42
PMCR- 2024/12/04
CRDT- 2022/12/29 09:13
PHST- 2024/12/04 00:00 [pmc-release]
PHST- 2023/12/17 09:42 [medline]
PHST- 2022/12/30 06:00 [pubmed]
PHST- 2022/12/29 09:13 [entrez]
AID - 10.1089/can.2022.0041 [pii]
AID - 10.1089/can.2022.0041 [doi]
PST - ppublish
SO  - Cannabis Cannabinoid Res. 2023 Dec;8(6):1106-1116. doi: 10.1089/can.2022.0041. 
      Epub 2022 Dec 28.